xB3-001 demonstrated lymphatic system
penetration and more selective tissue distribution with xB3-001
than trastuzumab alone
The Company has filed patent applications based
on these observations and those data may have broader
applicability
An updated version of the corporate
presentation is available for review at
www.bioasis.us/investors
Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the
“Company”), a pre-clinical,
research-stage biopharmaceutical company developing its
proprietary xB3 TM platform technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and
the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases, today
announced data using the Company’s lead investigational candidate
xB3-001 in an advanced positron emission tomography
and computed tomography (PET/CT) imaging study in
non-human primates suggest selective peripheral distribution. The
data also indicates penetration of the lymphatic system with
xB3-001.
“These findings with xB3-001 suggest that the Bioasis
platform can enhance the distribution of treatments that have their
efficacy limited by inability to penetrate relevant tissue
compartments,” said Prof. John H. Krystal, M.D., chairman, Bioasis
scientific advisory board (SAB); Robert L. McNeil, Jr., professor
of translational research, chair of the department of psychiatry,
and professor of neuroscience at the Yale University School of
Medicine and chief of psychiatry at Yale-New Haven Hospital.
In collaboration with Invicro LLC., whole-body distribution of
xB3-001 was examined in the study using advanced PET/CT imaging in
non-human primates. Data from this study suggest a more selective
peripheral distribution pattern for xB3-001 compared to trastuzumab
alone. Importantly, the data also indicate that the xB3 platform
has the potential to penetrate the lymphatic system as shown by the
accumulation of xB3-001 in the cervical lymph nodes, which is not
seen in trastuzumab alone.
“Together, both the peripheral distribution of xB3-001 and
penetration of the lymph nodes may indicate additional benefits of
xB3 fusions for patients with neurological and oncological
diseases,” said Mark Day, Ph.D., lead investigator of the research;
director, president and chief executive officer, Bioasis. “The
potential of these findings with the xB3 platform are truly
exciting and we look forward to conducting additional research as
it potentially opens significant opportunities for Bioasis.”
The lymphatic system is an important target for developing new
vaccines, cancer treatments and diagnostic agents. For example,
most solid cancers initially spread from the primary site via the
tumor’s surrounding lymphatics before hematological dissemination.
Targeting the lymphatic system by subcutaneous, intestinal and
pulmonary routes has been evaluated and subsequently utilized to
improve lymphatic penetration as well as retention of drug
molecules, reduce drug-related systemic toxicities and enhance
bioavailability of poorly soluble and unstable drugs. Lymphatic
imaging is an essential tool for the detection and staging of
cancer.
“The xB3-001 lymphatic and lymph node penetration observed in
the current study supports the utility of the xB3 platform for many
CNS and non-CNS disorders,” said Mario Saltarelli, M.D., Ph.D.,
Bioasis SAB member; former executive vice president and chief
medical officer, Syntimmune.
The Company has filed a patent application based on
these observations and those data may have broader
applicability.
“We are excited to collaborate with the strong team at Bioasis
and very eager to work together to generate what appear to be very
exciting data,” said Jack Hoppin, Ph.D., Bioasis SAB member;
co-founder and chief executive officer of Invicro LLC.
Bioasis also advises investors that an updated version of its
corporate presentation is available for review on its website at
www.bioasis.us/investors.
On behalf of the Board of Directors of Bioasis Technologies
Inc.Mark Day, Ph.D., Director, President & Chief Executive
Officer
ABOUT BIOASIS
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 TM platform, a proprietary technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and
the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the BBB represents the final
frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, along with other statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005830/en/
Bioasis Technologies, Inc.Catherine
London+1-917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Sep 2023 to Sep 2024